Nanologica (Q2 review): Stockpiling powder, awaiting conversion - Redeye

Nanologica's Q2 did not live up to expectations and the market focused on the cash position, sending the stock down around 20%. However, the outlook is more nuanced: the company has built a significant inventory, positioning it to meet demand and potentially extend its cash runway should production evaluations convert in a timely manner. Against our DCF valuation, the stock remains cheap, with order conversion and Syntagon profitability being the primary drivers.

Länk till analysen i sin helhet: https://www.redeye.se/research/1183147/nanologica-q2-review-stockpiling-powder-awaiting-conversion?utm_source=finwire&utm_medium=RSS